MedTrace Logo

RCT of Laser Therapy for GSM

NCT03288883 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-02-12

No results posted yet for this study

Summary

The aim of the current study is to assess whether the CO2-laser results in superior alleviation of GSM symptoms compare to Er:YAG-laser. Specifically, we will compare objective and subjective measurements of symptoms and clinical signs of GSM, between groups of postmenopausal women with GSM receiving treatment with CO2-laser or Er:YAG-laser.

Conditions

  • Genitourinary Syndrome of Menopause

Interventions

DEVICE

Photothermal Non-ablative Erbium:YAG-laser

Laser treatment of the vagina for GSM

DEVICE

Fractional Microablative CO2-laser

Laser treatment of the vagina for GSM

Sponsors & Collaborators

  • Alexandra Hospital, Athens, Greece

    collaborator OTHER

  • King's College Hospital NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2021-02-11
Completion
2021-02-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03288883 on ClinicalTrials.gov